Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Add To Watchlist

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > ARCH $4,000,000 funding from the National Research Council

View:

Post by Riverfolk on Apr 08, 2023 8:41pm

ARCH $4,000,000 funding from the National Research Council

The research and development funding from NRC IRAP will help support several sub-tasks needed to advance the LSALT peptide drug program.

These include:

dose escalation studies;
costs incurred by Arch during the Canadian Treatments for COVID-19 Phase III human trial;
manufacturing new drug product supply to support future non-COVID human trials;
the non-COVID Phase II trials (such as a cardiac surgery associated acute kidney injury trial) to gather more human data to support future drug approval;
and, additional non-clinical studies to discover potential biomarkers and to further understand the mechanism of action related to LSALT peptide.